Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CTNNB1 mutations, TERT polymorphism and CD8+ cell densities in resected hepatocellular carcinoma are associated with longer time to recurrence.

BMC cancer - 13 Aug 2022

Ambrozkiewicz Filip, Trailin Andriy, Červenková Lenka, Vaclavikova Radka, Hanicinec Vojtech, Allah Mohammad Al Obeed, Palek Richard, Třeška Vladislav, Daum Ondrej, Tonar Zbyněk, Liška Václav, Hemminki Kari

Abstract excerpt

BACKGROUND: Hepatocellular carcinoma (HCC) is a fatal disease characterized by early genetic alterations in telomerase reverse transcriptase promoter (TERTp) and β-catenin (CTNNB1) genes and immune cell activation in the tumor microenvironment. As a novel approach, we wanted to assess patient survival influenced by combined presence of mutations and densities of CD8+ cytotoxic T cells. METHODS: Tissue samples...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to beta Catenin
Share to Carcinoma, Hepatocellular

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CD8-Positive T-Lymphocytes

Share to Cell Count

Share to Liver Neoplasms

Share to Polymorphism, Single Nucleotide

Share to Telomerase

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 35962322
DOI: 10.1186/s12885-022-09989-0
PMCID: PMC9375422

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CTNNB1 mutations, TERT polymorphism and CD8+ cell densities in resected hepatocellular carcinoma are associated with longer time to recurrence.PMID 35962322Read ↗

TERT Promoter Mutations Combined with TP53 Mutations as Potential Biomarkers for Hepatocellular Carcinoma Recurrence and PrognosisSemantic proximity Read ↗

TERT-TP53 mutations: a novel biomarker pair for hepatocellular carcinoma recurrence and prognosisSemantic proximity Read ↗

Geographic and Viral Etiology Patterns of TERT Promoter and CTNNB1 Exon 3 Mutations in Hepatocellular Carcinoma: A Comprehensive ReviewSemantic proximity Read ↗

Tumor Mutational Burden as a Prognostic Biomarker for Relapse-Free Survival in Hepatocellular Carcinoma: Insights from Long-Term Follow-UpSemantic proximity Read ↗

Molecular Scoring of Hepatocellular Carcinoma for Predicting Metastatic Recurrence and Requirements of Systemic ChemotherapySemantic proximity Read ↗

Association of TERT promoter mutations with early recurrence in hepatocellular carcinoma: a subgroup analysis in a Vietnamese cohort.Semantic proximity Read ↗

Genetic alterations are related to clinicopathological features and risk of recurrence/metastasis of hepatocellular carcinoma.Semantic proximity Read ↗

Association of survival and genomic mutation signature with immunotherapy in patients with hepatocellular carcinomaSemantic proximity Read ↗

TERT promoter mutation predicts the prognosis value of patients with HBV- related HCC who underwent hepatectomySemantic proximity Read ↗

Association of Tert Promoter Mutations With Early Recurrence in Hepatocellular Carcinoma: A Subgroup Analysis in a Vietnamese CohortSemantic proximity Read ↗

Immunological and molecular correlates of disease recurrence after liver resection for hepatocellular carcinoma.Semantic proximity Read ↗

Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.